Fig. 3
The immune therapeutic benefit of the SIPS index. A The Kaplan–Meier estimate of the overall survival in BLCA cohort, divided by two SIPS subtypes. B The time-dependent ROC curve at 1/2-year OS in BLCA cohort. C The boxplot showed the levels of SIPS score of patients with different immunotherapy responses in BLCA cohort. D The waterfall plot illustrated the distribution of SIPS in patients with different immunotherapy responses in BLCA cohort. The Kaplan–Meier estimate of the (E) overall survival and F progress free survival of SKCM cohort, divided by two SIPS subtypes. G The boxplot showed the levels of SIPS score of patients with different immunotherapy responses in SKCM cohort. H The time-dependent ROC curve at 1/2-year OS in SKCM cohort. I The time-dependent ROC curve at 1/2-year PFS in SKCM cohort. J The Kaplan–Meier estimate of the progress free survival of NSCLC cohort, divided by two SIPS subtypes. K The time-dependent ROC curve at 1/2-year PFS in NSCLC cohort. L The Kaplan–Meier estimate of the relapse-free survival of GC cohort, divided by two SIPS subtypes. M The time-dependent ROC curve at 1/2-year of RFS in the NSCLC cohort. N The boxplot showing the levels of SIPS score of patients with different immunotherapy responses in BRCA cohort